URGN Q2 2018 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$364,000

Gross Profit

$46,00012.6% margin

Operating Income

-$18M-5064.3% margin

Net Income

-$18M-4952.2% margin

EPS (Diluted)

$-1.14

QoQ Revenue Growth

-24.3%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$122M

Total Liabilities

$8M

Stockholders' Equity

$114M

Cash & Equivalents

$119M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$364,000	$0	—
Gross Profit	$46,000	$0	—
Operating Income	-$18M	-$6M	-209.8%
Net Income	-$18M	-$6M	-190.8%